All In Biotech

Drug Trial Radar · NCT03813056

Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy

A Phase II, Interventional, Double-blind, Single-center Study of the Effects of Ripasudil on Cornea Clearing After Descemet Membrane Endothelial Keratoplasty in Subjects With Fuchs' Endothelial Corneal Dystrophy

Last checked: Nov 19, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

72

Planned (sponsor's estimate)

Start

Mar 25, 2019

Primary completion

Feb 1, 2025

Study completion Feb 1, 2025

Sponsor

Lead sponsor
Michael D. Straiko, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Lions VisionGift Research; Eye Bank Association of America
First posted
Jan 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Recently, published literature has reported that performing a descemetorhexis in combination with topical Rho kinase (ROCK) inhibitor therapy was successful in clearing edematous corneas in patients with Fuchs Endothelial Corneal Dystrophy. Ripasudil hydrochloride hydrate( Glanatec ophthalmic solution 0.4%), a potent ROCK inhibitor, has been approved in Japan since 2014 for ocular use in the treatment of glaucoma. Ripasudil acts as an IOP-lowering drug by affecting aqueous outflow through the trabecular meshwork and Schlemm's canal. The goal of this study is to test the potential benefits of Ripasudil therapy administered after Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. We believe that performing a standard DMEK surgery in combination with Ripasudil treatment in patients with Fuchs Endothelial Corneal Dystrophy could accelerate endothelial cell healing and clear edematous corneas faster, with less post-operative complications.

Conditions

  • Fuchs Endothelial Dystrophy

Interventions

  • GlanatecDrug

    Rho kinase Inhibitor

  • Optive, Ophthalmic SolutionDrug

    artificial tears (placebo)

  • Descemet Membrane Endothelial KeratoplastyProcedure

    Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to corneal clearanceTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Devers Eye Institute

    Portland, Oregon · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.